Norwegian Diabetes Association Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02569684
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Norwegian Diabetes Association

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glucose Intolerance (Phase 2)

Glucose Metabolism Disorders (Phase 2)

Hypersensitivity (Phase 2)

Insulin Resistance (Phase 2)

Metabolic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 6